LIXT Lixte Biotechnology Holdings, Inc.
Price Chart
Executive Summary
Lixte Biotechnology filed its Q1 2026 10-Q, reporting an EPS of -$0.27 with no consensus estimate available. The press release focuses on operational progress for lead compound LB-100 and the Liora proton therapy subsidiary, but provides no financial results or guidance. For a clinical-stage biotech with no revenue, this is a routine quarterly update with no material financial data to move the stock.
Actionable Insight
This is a routine quarterly filing with no financial surprises or guidance. Monitor for future clinical trial readouts for LB-100 and Liora's LIGHT System as the primary catalysts. The stock's recent volatility (T+20 +75% on prior neutral filing) suggests low-float dynamics rather than fundamental news.
Key Facts
- EPS reported at -$0.27 for Q1 2026, no consensus estimate available
- No revenue reported — company is pre-revenue clinical-stage
- Press release contains no financial results, guidance, or material financial data
- Operational highlights: LB-100 ovarian cancer trial expanded, Liora proton therapy integration progressing
- No guidance provided; no earnings call or financial discussion in the release
Financial Impact
No financial data reported — pre-revenue clinical-stage biotech with $58M market cap
Risk Factors
- No revenue or near-term commercialization path for LB-100 or Liora
- Clinical-stage biotech with binary pipeline risk — trial failures could be catastrophic
- Low market cap ($58M) and potential for dilutive financing
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295466 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
9d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 17, 2026
5w ago
|
8-K
| $3.44 $4.70 | ▲ +36.63% | ▲ +32.43% | $5.88 (+70.93%) |
|
Apr 13, 2026
5w ago
|
Press Release
| $2.93 $5.15 | ▲ +75.77% | ▲ +68.04% | $5.88 (+100.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access